| Theme | Precancerous Conditions and Cancer High-risk Lesions in the Colorectum | |
|---|---|---|
| Title | Anal Canal Cancer | |
| Publish Date | 2010/09 | |
| Author | Kazuhiro Watanabe | Department of Surgery, Tohoku University Graduate School of Medicine |
| Author | Chikashi Shibata | Department of Surgery, Tohoku University Graduate School of Medicine |
| Author | Koh Miura | Department of Surgery, Tohoku University Graduate School of Medicine |
| Author | Takeshi Naito | Department of Surgery, Tohoku University Graduate School of Medicine |
| Author | Hitoshi Ogawa | Department of Surgery, Tohoku University Graduate School of Medicine |
| Author | Iwao Sasaki | Department of Surgery, Tohoku University Graduate School of Medicine |
| [ Summary ] | Chemoradiation therapy with a combination of mitomycin C and 5-FU is the standard primary therapy for anal canal cancer in Europe and the United States, while, surgery (abdomino-perineal resection) is still the major therapy for anal canal cancer in Japan. JCOG0903 (A phase I/II trial of chemoradiotherapy concurrent with S-1 plus mitomycin C in patients with clinical stage II/III squamous cell carcinoma of the anal canal) has just started and we expect to produce evidence of the effectiveness of chemoradiotherapy for anal canal cancer in Japan. | |